Michael T Milano1, Jimm Grimm2, Andrzej Niemierko3, Scott G Soltys4, Vitali Moiseenko5, Kristin J Redmond6, Ellen Yorke7, Arjun Sahgal8, Jinyu Xue9, Anand Mahadevan2, Alexander Muacevic10, Lawrence B Marks11, Lawrence R Kleinberg6. 1. Department of Radiation Oncology, University of Rochester, Rochester, New York. Electronic address: michael_milano@urmc.rochester.edu. 2. Department of Radiation Oncology, Geisinger Cancer Institute, Danville, Pennsylvania. 3. Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts. 4. Department of Radiation Oncology, Stanford University Medical Center, Stanford, California. 5. Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California. 6. Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland. 7. Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York City, New York. 8. Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada. 9. Department of Radiation Oncology, NYU Langone Medical Center, New York City, NY. 10. European Cyberknife Center Munich-Großhadern, Munich, Germany. 11. Department of Radiation Oncology and Lineberger Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
Abstract
PURPOSE: As part of the American Association of Physicists in Medicine Working Group on Stereotactic Body Radiotherapy investigating normal tissue complication probability (NTCP) after hypofractionated radiation therapy, data from published reports (PubMed indexed 1995-2018) were pooled to identify dosimetric and clinical predictors of radiation-induced brain toxicity after single-fraction stereotactic radiosurgery (SRS) or fractionated stereotactic radiosurgery (fSRS). METHODS AND MATERIALS: Eligible studies provided NTCPs for the endpoints of radionecrosis, edema, or symptoms after cranial SRS/fSRS and quantitative dose-volume metrics. Studies of patients with only glioma, meningioma, vestibular schwannoma, or brainstem targets were excluded. The data summary and analyses focused on arteriovenous malformations (AVM) and brain metastases. RESULTS: Data from 51 reports are summarized. There was wide variability in reported rates of radionecrosis. Available data for SRS/fSRS for brain metastases were more amenable to NTCP modeling than AVM data. In the setting of brain metastases, SRS/fSRS-associated radionecrosis can be difficult to differentiate from tumor progression. For single-fraction SRS to brain metastases, tissue volumes (including target volumes) receiving 12 Gy (V12) of 5 cm3, 10 cm3, or >15 cm3 were associated with risks of symptomatic radionecrosis of approximately 10%, 15%, and 20%, respectively. SRS for AVM was associated with modestly lower rates of symptomatic radionecrosis for equivalent V12. For brain metastases, brain plus target volume V20 (3-fractions) or V24 (5-fractions) <20 cm3 was associated with <10% risk of any necrosis or edema, and <4% risk of radionecrosis requiring resection. CONCLUSIONS: The risk of radionecrosis after SRS and fSRS can be modeled as a function of dose and volume treated. The use of fSRS appears to reduce risks of radionecrosis for larger treatment volumes relative to SRS. More standardized dosimetric and toxicity reporting is needed to facilitate future pooled analyses that can refine predictive models of brain toxicity risks.
PURPOSE: As part of the American Association of Physicists in Medicine Working Group on Stereotactic Body Radiotherapy investigating normal tissue complication probability (NTCP) after hypofractionated radiation therapy, data from published reports (PubMed indexed 1995-2018) were pooled to identify dosimetric and clinical predictors of radiation-induced brain toxicity after single-fraction stereotactic radiosurgery (SRS) or fractionated stereotactic radiosurgery (fSRS). METHODS AND MATERIALS: Eligible studies provided NTCPs for the endpoints of radionecrosis, edema, or symptoms after cranial SRS/fSRS and quantitative dose-volume metrics. Studies of patients with only glioma, meningioma, vestibular schwannoma, or brainstem targets were excluded. The data summary and analyses focused on arteriovenous malformations (AVM) and brain metastases. RESULTS: Data from 51 reports are summarized. There was wide variability in reported rates of radionecrosis. Available data for SRS/fSRS for brain metastases were more amenable to NTCP modeling than AVM data. In the setting of brain metastases, SRS/fSRS-associated radionecrosis can be difficult to differentiate from tumor progression. For single-fraction SRS to brain metastases, tissue volumes (including target volumes) receiving 12 Gy (V12) of 5 cm3, 10 cm3, or >15 cm3 were associated with risks of symptomatic radionecrosis of approximately 10%, 15%, and 20%, respectively. SRS for AVM was associated with modestly lower rates of symptomatic radionecrosis for equivalent V12. For brain metastases, brain plus target volume V20 (3-fractions) or V24 (5-fractions) <20 cm3 was associated with <10% risk of any necrosis or edema, and <4% risk of radionecrosis requiring resection. CONCLUSIONS: The risk of radionecrosis after SRS and fSRS can be modeled as a function of dose and volume treated. The use of fSRS appears to reduce risks of radionecrosis for larger treatment volumes relative to SRS. More standardized dosimetric and toxicity reporting is needed to facilitate future pooled analyses that can refine predictive models of brain toxicity risks.
Authors: Christopher Herbert; Vitali Moiseenko; Michael McKenzie; Gary Redekop; Fred Hsu; Ermias Gete; Brad Gill; Richard Lee; Kurt Luchka; Charles Haw; Andrew Lee; Brian Toyota; Montgomery Martin Journal: Int J Radiat Oncol Biol Phys Date: 2011-12-28 Impact factor: 7.038
Authors: Penny K Sneed; Joe Mendez; Johanna G M Vemer-van den Hoek; Zachary A Seymour; Lijun Ma; Annette M Molinaro; Shannon E Fogh; Jean L Nakamura; Michael W McDermott Journal: J Neurosurg Date: 2015-05-15 Impact factor: 5.115
Authors: Yazan Abuodeh; Kamran A Ahmed; Arash O Naghavi; Puja S Venkat; Siriporn Sarangkasiri; Peter A S Johnstone; Arnold B Etame; Hsiang-Hsuan Michael Yu Journal: World Neurosurg Date: 2016-02-26 Impact factor: 2.104
Authors: Victor A Levin; Luc Bidaut; Ping Hou; Ashok J Kumar; Jeffrey S Wefel; B Nebiyou Bekele; Jai Grewal; Sujit Prabhu; Monica Loghin; Mark R Gilbert; Edward F Jackson Journal: Int J Radiat Oncol Biol Phys Date: 2011-04-01 Impact factor: 7.038
Authors: L Miyawaki; C Dowd; W Wara; B Goldsmith; N Albright; P Gutin; V Halbach; G Hieshima; R Higashida; B Lulu; L Pitts; M Schell; V Smith; K Weaver; C Wilson; D Larson Journal: Int J Radiat Oncol Biol Phys Date: 1999-07-15 Impact factor: 7.038
Authors: Fred G Barker; William E Butler; Sue Lyons; Ethan Cascio; Christopher S Ogilvy; Jay S Loeffler; Paul H Chapman Journal: J Neurosurg Date: 2003-08 Impact factor: 5.115
Authors: J Broemme; J Abu-Isa; R Kottke; J Beck; R Wiest; M Malthaner; D Schmidhalter; A Raabe; D M Aebersold; A Pica Journal: Strahlenther Onkol Date: 2013-08-11 Impact factor: 3.621
Authors: Hideho Okada; Michael Weller; Raymond Huang; Gaetano Finocchiaro; Mark R Gilbert; Wolfgang Wick; Benjamin M Ellingson; Naoya Hashimoto; Ian F Pollack; Alba A Brandes; Enrico Franceschi; Christel Herold-Mende; Lakshmi Nayak; Ashok Panigrahy; Whitney B Pope; Robert Prins; John H Sampson; Patrick Y Wen; David A Reardon Journal: Lancet Oncol Date: 2015-11 Impact factor: 41.316
Authors: Luke Peng; Jimm Grimm; Chengcheng Gui; Colette J Shen; Kristin J Redmond; Lindsey Sloan; Sarah Hazell; Joseph Moore; Ellen Huang; Nicholas Spoleti; Wolfram Laub; Harry Quon; Chetan Bettegowda; Michael Lim; Lawrence R Kleinberg Journal: Surg Neurol Int Date: 2019-03-15
Authors: Hao Gao; Jiulong Liu; Yuting Lin; Gregory N Gan; Guillem Pratx; Fen Wang; Katja Langen; Jeffrey D Bradley; Ronny L Rotondo; Harold H Li; Ronald C Chen Journal: Med Phys Date: 2021-12-07 Impact factor: 4.506
Authors: Jimm Grimm; Lawrence B Marks; Andrew Jackson; Brian D Kavanagh; Jinyu Xue; Ellen Yorke Journal: Int J Radiat Oncol Biol Phys Date: 2021-05-01 Impact factor: 8.013
Authors: Vitali Moiseenko; Lawrence B Marks; Jimm Grimm; Andrew Jackson; Michael T Milano; Jona A Hattangadi-Gluth; Minh-Phuong Huynh-Le; Niclas Pettersson; Ellen Yorke; Issam El Naqa Journal: Int J Radiat Oncol Biol Phys Date: 2020-12-23 Impact factor: 8.013
Authors: Paola Anna Jablonska; Joaquim Bosch-Barrera; Diego Serrano; Manuel Valiente; Alfonso Calvo; Javier Aristu Journal: Cancers (Basel) Date: 2021-04-29 Impact factor: 6.639
Authors: Kelly J McKelvey; Amanda L Hudson; Heather Donaghy; Shihani P Stoner; Helen R Wheeler; Connie I Diakos; Viive M Howell Journal: Radiat Oncol Date: 2022-01-25 Impact factor: 3.481
Authors: Gustavo R Sarria; Zuzanna Smalec; Thomas Muedder; Jasmin A Holz; Davide Scafa; David Koch; Stephan Garbe; Matthias Schneider; Motaz Hamed; Hartmut Vatter; Ulrich Herrlinger; Frank A Giordano; Leonard Christopher Schmeel Journal: Front Oncol Date: 2021-10-28 Impact factor: 6.244